Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-05-01
Study Completion Date
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Subjects on a standard regimen of tiopronin (cystine binding thiol drug; CBTD) plus prescribed first-line therapy (i.e. on a hydration, alkali therapy and dietary restriction) who are failing therapy will be selected for this trial.
After completing informed consent, the subject will have Screening consisting of medication history and physical examination with vital signs. Samples of blood and urine will be taken for clinical laboratory and urinalysis. Patients will undergo a 12-lead ECG test. A history of side effects with current CBTD as well as laboratory recordings of abnormalities attributable to treatment will also be recorded.
Subjects will be dosed in a sequential manner, starting with the low dose group (300 mg/day), then proceeding to the 600 mg.day dose group.. Safety and tolerability will be monitored closely by an Independent Medical Monitor (IMM) and based on the IMM's assessment that it is safe to proceed to the higher dose (600 mg/day), subsequent subjects will be enrolled into that group. Up to 15 subjects each will be enrolled into either Group A or Group B.
After 7 days on the assigned bucillamine dose, a 24-hour urine sample will be taken and after completing the Day 8 safety visit, subjects will undergo a 7 day washout where no CBTDs will be taken. Thereafter, subjects will be allowed to resume their originally prescribed CBTDs under Investigator's supervision.
One week following study drug discontinuation, subjects will return to the clinic for follow-up safety assessments.
After completing informed consent, the subject will have Screening consisting of medication history and physical examination with vital signs. Samples of blood and urine will be taken for clinical laboratory and urinalysis. Patients will undergo a 12-lead ECG test. A history of side effects with current CBTD as well as laboratory recordings of abnormalities attributable to treatment will also be recorded.
Subjects will be dosed in a sequential manner, starting with the low dose group (300 mg/day), then proceeding to the 600 mg.day dose group.. Safety and tolerability will be monitored closely by an Independent Medical Monitor (IMM) and based on the IMM's assessment that it is safe to proceed to the higher dose (600 mg/day), subsequent subjects will be enrolled into that group. Up to 15 subjects each will be enrolled into either Group A or Group B.
After 7 days on the assigned bucillamine dose, a 24-hour urine sample will be taken and after completing the Day 8 safety visit, subjects will undergo a 7 day washout where no CBTDs will be taken. Thereafter, subjects will be allowed to resume their originally prescribed CBTDs under Investigator's supervision.
One week following study drug discontinuation, subjects will return to the clinic for follow-up safety assessments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).
NCT06736288
Respiratory Infection
Lower Respiratory Tract Infection (LRTI)
RECRUITING
PHASE4
Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00581945
Chronic Obstructive Pulmonary Disease
COMPLETED
PHASE1/PHASE2
A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis
NCT00006280
Cystic Fibrosis
COMPLETED
PHASE2
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
NCT02679729
Cystic Fibrosis
COMPLETED
PHASE1
Safety, Tolerability, and Pharmacokinetics of SPL84 in Healthy Volunteers
NCT06217952
Cystic Fibrosis
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects on a standard regimen of tiopronin (cystine binding thiol drug; CBTD) plus prescribed first-line therapy (i.e. on a hydration, alkali therapy and dietary restriction) who are failing therapy will be selected for this trial.
Subjects will be encouraged to continue their usual self-selected ad-lib diets, fluid and alkali regimen and keep this regimen consistent throughout the duration of the study. Study diaries will be kept to assess consistency and drug compliance.
After completing informed consent, the enrolled subject will have an initial Screening interview. During the interview the patient will be assessed for symptoms of renal colic as well as asked about any scheduled urological procedures (a positive indication is an exclusionary criteria). At the Screening visit, a medication history will be taken and a complete physical examination, including vital signs will be done. Samples of blood and urine will be taken for clinical laboratory and urinalysis. Patients will then undergo a 12-lead ECG test.
A history of side effects with current CBTD as well as laboratory recordings of abnormalities attributable to treatment will also be recorded.
Enrolled subjects will be dosed in a sequential manner, starting with the low dose group (300 mg/day). Safety and tolerability will be monitored closely by an Independent Medical Monitor (IMM) and based on the IMM's assessment that it is safe to proceed to the higher dose (600 mg/day), subsequent subjects will be enrolled into that group. Up to 15 subjects each will be enrolled into either Group A or Group B.
Subjects will stop taking their current CBTDs for 7 days and perform a 24-hour urine collection on Day-7 and report for Day 1 Visit .
Subjects enrolled into Group A will start taking bucillamine tablets orally, three times a day preferably 1hr before or 2hrs after meals in the following sequence; 100 mg (1 tab) in the morning; 100 mg (1 tab) at noon and 100 mg (1 tab) at night. This drug regimen will continue for 7 days. Safety Visits are scheduled on Day 3 and Day 8 (End of Study Visit). Furthermore, on Day 7 a 24-hour urine collection will be performed. Instructions for handling this sample will be provided in a separate manual.
Subjects enrolled into Group B, will start taking bucillamine tablets orally, three times a day preferably 1hr before or 2hrs after meals in the following sequence; 200 mg (2 tabs) in the morning; 200 mg (2 tabs) at noon and 200 mg (2 tabs) at night. This drug regimen will continue for 7 days. Safety Visits are scheduled on Day 3 and Day 8 (End of Study Visit). Furthermore, on Day 7 a 24-hour urine collection will be performed. Instructions for handling this sample will be provided in a separate manual.
After 7 days on the assigned bucillamine dose and after providing the 24-hour urine sample, and after completing the Day 8 safety visit, subjects will undergo a 7 day washout where no CBTDs will be taken. Thereafter, subjects will be allowed to resume their originally prescribed CBTDs under Investigator's supervision.
One week following study drug discontinuation, subjects will return to the clinic for follow-up safety assessments.
Subjects will be encouraged to continue their usual self-selected ad-lib diets, fluid and alkali regimen and keep this regimen consistent throughout the duration of the study. Study diaries will be kept to assess consistency and drug compliance.
After completing informed consent, the enrolled subject will have an initial Screening interview. During the interview the patient will be assessed for symptoms of renal colic as well as asked about any scheduled urological procedures (a positive indication is an exclusionary criteria). At the Screening visit, a medication history will be taken and a complete physical examination, including vital signs will be done. Samples of blood and urine will be taken for clinical laboratory and urinalysis. Patients will then undergo a 12-lead ECG test.
A history of side effects with current CBTD as well as laboratory recordings of abnormalities attributable to treatment will also be recorded.
Enrolled subjects will be dosed in a sequential manner, starting with the low dose group (300 mg/day). Safety and tolerability will be monitored closely by an Independent Medical Monitor (IMM) and based on the IMM's assessment that it is safe to proceed to the higher dose (600 mg/day), subsequent subjects will be enrolled into that group. Up to 15 subjects each will be enrolled into either Group A or Group B.
Subjects will stop taking their current CBTDs for 7 days and perform a 24-hour urine collection on Day-7 and report for Day 1 Visit .
Subjects enrolled into Group A will start taking bucillamine tablets orally, three times a day preferably 1hr before or 2hrs after meals in the following sequence; 100 mg (1 tab) in the morning; 100 mg (1 tab) at noon and 100 mg (1 tab) at night. This drug regimen will continue for 7 days. Safety Visits are scheduled on Day 3 and Day 8 (End of Study Visit). Furthermore, on Day 7 a 24-hour urine collection will be performed. Instructions for handling this sample will be provided in a separate manual.
Subjects enrolled into Group B, will start taking bucillamine tablets orally, three times a day preferably 1hr before or 2hrs after meals in the following sequence; 200 mg (2 tabs) in the morning; 200 mg (2 tabs) at noon and 200 mg (2 tabs) at night. This drug regimen will continue for 7 days. Safety Visits are scheduled on Day 3 and Day 8 (End of Study Visit). Furthermore, on Day 7 a 24-hour urine collection will be performed. Instructions for handling this sample will be provided in a separate manual.
After 7 days on the assigned bucillamine dose and after providing the 24-hour urine sample, and after completing the Day 8 safety visit, subjects will undergo a 7 day washout where no CBTDs will be taken. Thereafter, subjects will be allowed to resume their originally prescribed CBTDs under Investigator's supervision.
One week following study drug discontinuation, subjects will return to the clinic for follow-up safety assessments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cystinuria
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Dosing will occur sequentially from low to high dose: The 600 mg bucillamine dose group (Arm A) will enroll first, then after safety is assured, the 900 mg bucillamine dose group will enroll.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
The study is unmasked, i.e., is open label.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Group A
Bucillamine 300 mg/day
Group Type
EXPERIMENTAL
Bucillamine
Intervention Type
DRUG
Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
Dose Group B
Bucillamine 600 mg/day
Group Type
EXPERIMENTAL
Bucillamine
Intervention Type
DRUG
Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bucillamine
Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects of any gender and of any race ≥18 and ≤80 years of age
2. Subjects with proven cystinuria who are failing their standard drug therapy of tiopronin plus first-line therapy (hydration, alkali and diet restriction) and who meet the following criteria.
* formed new stones while taking a thiol.
* had increase in stone size of pre-existing stones while taking a thiol.
* had a urologic intervention for stones while taking a thiol
3. Subjects must be able to reliably urinate in a collection vessel and measure urine volume
4. Subjects must have documentation of a stable complete blood count (CBC) and urinalysis (UA) in the 6 months prior to date of enrollment
5. Subjects may have a history of but not currently active CNS disorders or symptoms/effects (e.g., headache)
6. Subjects must have adequate organ function, evidenced by the following laboratory results within 30 days prior to enrollment:
* Absolute neutrophil count \>2000 cells/mm
* Platelet count \>140,000 cells/mm3
* Hemoglobin \>11.0 g/dl
* Albumin ≥2.5 g/dl
* Total bilirubin ≤1.5 upper limit of normal (ULN)
* SGOT (aspartate aminotransferase \[AST\]), SGPT (alanine aminotransferase \[ALT\]), and alkaline phosphatase (ALP)
≤ 2.5 x ULN
* eGFR \>60 ml/min/173m 2 based on Modification of Diet and Renal Disease (MDRD) Study equation which includes the variables of creatinine, age, sex and race
7. Female subject who has been post-menopausal for at least 24 consecutive months, or women who have undergone surgical sterilization, (e.g. hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy) is eligible without requiring the use of a contraceptive methods described in Inclusion #8
8. For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception:
* Acceptable forms of should include two of the following:
* Placement of intrauterine device (IUD) or intrauterine system (IUS)
* Condom with spermicidal foam/gel/film/cream/suppository
* Diaphragm or cervical/vault caps with spermicidal foam/gel/film/cream/suppository
* The above contraception is not a requirement in the case of any of the following:
* Subject is surgically sterilized
* Subject has had no menstrual period for 12 consecutive months
* Contraception use should continue for the duration of the study treatment and for at least 3 months after the last dose of study treatment Periodic abstinence (e.g., calendar ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
9. Subjects must be willing and able to give written informed consent
2. Subjects with proven cystinuria who are failing their standard drug therapy of tiopronin plus first-line therapy (hydration, alkali and diet restriction) and who meet the following criteria.
* formed new stones while taking a thiol.
* had increase in stone size of pre-existing stones while taking a thiol.
* had a urologic intervention for stones while taking a thiol
3. Subjects must be able to reliably urinate in a collection vessel and measure urine volume
4. Subjects must have documentation of a stable complete blood count (CBC) and urinalysis (UA) in the 6 months prior to date of enrollment
5. Subjects may have a history of but not currently active CNS disorders or symptoms/effects (e.g., headache)
6. Subjects must have adequate organ function, evidenced by the following laboratory results within 30 days prior to enrollment:
* Absolute neutrophil count \>2000 cells/mm
* Platelet count \>140,000 cells/mm3
* Hemoglobin \>11.0 g/dl
* Albumin ≥2.5 g/dl
* Total bilirubin ≤1.5 upper limit of normal (ULN)
* SGOT (aspartate aminotransferase \[AST\]), SGPT (alanine aminotransferase \[ALT\]), and alkaline phosphatase (ALP)
≤ 2.5 x ULN
* eGFR \>60 ml/min/173m 2 based on Modification of Diet and Renal Disease (MDRD) Study equation which includes the variables of creatinine, age, sex and race
7. Female subject who has been post-menopausal for at least 24 consecutive months, or women who have undergone surgical sterilization, (e.g. hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy) is eligible without requiring the use of a contraceptive methods described in Inclusion #8
8. For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception:
* Acceptable forms of should include two of the following:
* Placement of intrauterine device (IUD) or intrauterine system (IUS)
* Condom with spermicidal foam/gel/film/cream/suppository
* Diaphragm or cervical/vault caps with spermicidal foam/gel/film/cream/suppository
* The above contraception is not a requirement in the case of any of the following:
* Subject is surgically sterilized
* Subject has had no menstrual period for 12 consecutive months
* Contraception use should continue for the duration of the study treatment and for at least 3 months after the last dose of study treatment Periodic abstinence (e.g., calendar ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
9. Subjects must be willing and able to give written informed consent
Exclusion Criteria
1. Subjects with renal colic
2. Subjects who are scheduled to undergo a surgical procedure
3. Subjects on D-penicillamine (see page 35 for explanation)
4. Subjects with cancer
5. Subjects with acute or chronic infections including HIV, tuberculosis, hepatitis B or hepatitis C
6. Patients with proteinuria ≥30 mg that is confirmed on repeat laboratory assessment within 24 hours
7. Subjects with QTc interval \>450 ms
8. A history of, hypokalemia and family history of Long QT syndrome
9. Use of concomitant medications that may prolong QT/QTc interval
10. Patients with significant heart failure and activity impairment (Class III-IV of the New York Heart Association (NYHA)
11. Subjects with serious hepatic disorder (Child-Pugh scores B or C)
12. Subjects with a history of alcohol or substance abuse within the 12 months prior to enrollment
13. Subjects with history of or active blood dyscrasia such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia.
14. Subjects with Coagulopathy (regardless if controlled by pharmacotherapy or not)
15. Subjects who have any concomitant illness (including active significant infection) or other finding that, in the opinion of the Investigator, would confound the study data or place the subject at unacceptable risk if the subject were to participate in the study, or that would require frequent adjustments in concomitant medications during the course of the study
16. Use of any investigational drug within 30 days prior to enrollment
17. Subjects currently participating in another research study or anticipated to enroll in such during participation in this study
18. Subjects for whom informed consent cannot be obtained
2. Subjects who are scheduled to undergo a surgical procedure
3. Subjects on D-penicillamine (see page 35 for explanation)
4. Subjects with cancer
5. Subjects with acute or chronic infections including HIV, tuberculosis, hepatitis B or hepatitis C
6. Patients with proteinuria ≥30 mg that is confirmed on repeat laboratory assessment within 24 hours
7. Subjects with QTc interval \>450 ms
8. A history of, hypokalemia and family history of Long QT syndrome
9. Use of concomitant medications that may prolong QT/QTc interval
10. Patients with significant heart failure and activity impairment (Class III-IV of the New York Heart Association (NYHA)
11. Subjects with serious hepatic disorder (Child-Pugh scores B or C)
12. Subjects with a history of alcohol or substance abuse within the 12 months prior to enrollment
13. Subjects with history of or active blood dyscrasia such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia.
14. Subjects with Coagulopathy (regardless if controlled by pharmacotherapy or not)
15. Subjects who have any concomitant illness (including active significant infection) or other finding that, in the opinion of the Investigator, would confound the study data or place the subject at unacceptable risk if the subject were to participate in the study, or that would require frequent adjustments in concomitant medications during the course of the study
16. Use of any investigational drug within 30 days prior to enrollment
17. Subjects currently participating in another research study or anticipated to enroll in such during participation in this study
18. Subjects for whom informed consent cannot be obtained
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Revive Therapeutics, Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama - Department of Urology
Birmingham, Alabama, United States
Site Status
RECRUITING
Massachusette General Hospital
Boston, Massachusetts, United States
Site Status
RECRUITING
New York University School of Medicine
New York, New York, United States
Site Status
RECRUITING
Omega Medical Research
Warwick, Rhode Island, United States
Site Status
RECRUITING
University of Wisconsin School of Medicane and Public Health
Madison, Wisconsin, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REV401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
NCT00388505
COMPLETED
PHASE3
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers
NCT02259959
COMPLETED
PHASE1
Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients
NCT02172534
COMPLETED
PHASE1
Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2
NCT02178059
COMPLETED
PHASE1
Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis
NCT00004829
COMPLETED
PHASE3
Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
NCT06238856
COMPLETED
PHASE1
Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™
NCT04249531
UNKNOWN
PHASE1
A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
NCT01322594
COMPLETED
PHASE1
Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex
NCT02212587
COMPLETED
PHASE1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects
NCT03830125
COMPLETED
PHASE1
Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
NCT01315691
WITHDRAWN
PHASE3
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051
NOT_YET_RECRUITING
PHASE2
US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study
NCT00515164
COMPLETED
PHASE2
A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
NCT02950805
COMPLETED
PHASE1
BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function
NCT02172118
COMPLETED
PHASE1
Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
NCT00558844
COMPLETED
PHASE1/PHASE2
Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
NCT00125346
TERMINATED
PHASE3
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
NCT06193031
COMPLETED
PHASE1
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
NCT05865886
COMPLETED
PHASE2
Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients
NCT02483637
COMPLETED
NA
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
NCT01775137
COMPLETED
PHASE4
Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172391
COMPLETED
PHASE3
Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris® Rectal Aerosol Foam
NCT02800824
COMPLETED
PHASE1